Precise Sciences Company (NASDAQ:EXAS) reported better-than-expected third-quarter monetary outcomes and raised its FY25 gross sales steering above estimates on Monday.
Precise Sciences reported quarterly earnings of 24 cents per share which beat the analyst consensus estimate of a lack of 7 cents per share. The corporate reported quarterly gross sales of $850.739 million which beat the analyst consensus estimate of $810.178 million.
Precise Sciences raised its FY2025 gross sales steering from $3.130 billion-$3.170 billion to $3.220 billion-$3.235 billion.
“Precise Sciences continues to advance our mission to stop most cancers and detect it earlier via a relentless deal with sufferers,” mentioned Kevin Conroy, chairman and CEO. “Our third quarter outcomes replicate the facility of our patient-centric platform and our trusted manufacturers, Cologuard® and Oncotype DX®. The momentum we’re constructing is fueling progress, advancing modern new checks like Cancerguard, and strengthening our monetary efficiency.”
Precise Sciences shares gained 3.5% to shut at $66.98 on Monday.
These analysts made modifications to their worth targets on Precise Sciences following earnings announcement.
- BTIG analyst Mark Massaro maintained Precise Sciences with a Purchase and raised the value goal from $75 to $85.
- Stifel analyst Daniel Arias maintained Precise Sciences with a Purchase and raised the value goal from $67 to $80.
- Barclays analyst Luke Sergott maintained the inventory with an Chubby ranking and boosted the value goal from $65 to $77.
Contemplating shopping for EXAS inventory? Right here’s what analysts assume:
Picture through Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
